

PATTERNS OF METHAMPHETAMINE USE AND ITS ASSOCIATIONS WITH PSYCHIATRIC SYMPTOMS IN PATIENTS UPON ADMISSION AT THE NATIONAL REHABILITATION CENTER LIDO BOGOR, INDONESIA

ROHMANIKA¹, WAWAIMULI AROZAL^{2*}, MELVA LOUISA², ANGGI GAYATRI², ARIA KEKALIH³, JEFMAN EFENDI MARZUKI HY^{1,4}, ERNIAWATI LESTARI^{1,5}, DIAH SETIA UTAMI⁵

¹Clinical Pharmacology Postgraduate Program, Departemen of Pharmacology and Therapeutics, Faculty of Medicine, Universitas Indonesia, Jakarta, 10430, Indonesia, ²Department of Pharmacology and Therapeutics, Faculty of Medicine, Universitas Indonesia, Jakarta, 10430, Indonesia, ³Departemen of Community Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta, 10430, Indonesia, ⁴Department of Pharmacology, Faculty of Medicine, Universitas Surabaya, Surabaya, 60293, Indonesia, ⁵National Narcotics Control Board of Indonesia, Jakarta, 13630, Indonesia
*Email: wawaimuli.arozal@ui.ac.id

Received: 18 Sep 2022, Revised and Accepted: 08 Nov 2022

ABSTRACT

Objective: Methamphetamine (MA) is a substance that is heavily abused worldwide. This present study aimed to investigate the association between the patterns of methamphetamine use and psychiatric symptoms in patients upon admission at The National Rehabilitation Center, Lido Bogor.

Methods: This was a cross-sectional study of MA abusers during the period of January 2016–December 2018 at The National Rehabilitation Center, Lido, Bogor. This study was done by assessing medical records. The inclusion criteria were MA abusers at the age of 18 y and above. Assessment of psychiatric symptoms was evaluated using Addiction Severity Index (ASI). Microsoft Excel and SPSS version 22.0 were used to process the data.

Results: The inclusion criteria were fulfilled by 1842 MA abusers. We found that 770 (41.8%) of MA abusers were assessed with psychiatric symptoms according to ASI. Depression was the most prevalent psychiatric symptom (31.9%), followed by anxiety (24.5%), and psychosis (8.9%). According to the results of multivariate analysis, the demographic profile and the mode of MA administration that are associated with the psychiatric symptoms were: female [odds ratio (OR): 1.95; 95% confidence interval (CI): 1.25–2.96, $p < 0.001$], 5-year duration of use [OR 1.43; 95% CI: 1.43 (1.19–1.73), $p < 0.001$], smoking as the route of administration [OR 1.3; 95% CI: 1.08–1.56, $p < 0.001$, $p = 0.006$], and concomitant use with other narcotics [OR 1.76; 95% CI: 1.46–2.13, $p < 0.001$].

Conclusion: Among MA abusers admitted to The National Rehabilitation Center, the main factors associated with psychiatric symptoms were: female, long duration of use, smoking as the route of administration, and concomitant use with other narcotics.

Keywords: Addiction severity index (ASI), Methamphetamine, Narcotics, Rehabilitation, Substance abuse

© 2022 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (<https://creativecommons.org/licenses/by/4.0/>) DOI: <https://dx.doi.org/10.22159/ijap.2022.v14s5.16> Journal homepage: <https://innovareacademics.in/journals/index.php/ijap>

INTRODUCTION

Substance abuse is a global problem that has invaded many facets of society. According to The United Nations Office on Drugs and Crime (UNODC), in 2018, around 269 million (5.4%) of the world's population aged 15–64 y had used narcotics and drugs at least once in their life [1]. While the Indonesian data, from The National Narcotics Agency (BNN) and the Indonesian Institute of Sciences (LIPI), showed that the national prevalence rate in 2019 was approximately 4.5 million or 2.4% of the population that were known to drug abusers. This data showed there were an increased prevalence rate in the last 2 y [2, 3].

Among the substances commonly abused, MA is the second most often used substance after marijuana. MA abusers were the most common patients admitted to rehabilitation facilities between 2015 and 2017 [2, 3]. MA is a substance belongs to the amphetamine-type stimulant (ATS) class, as well as the sympathomimetic amine phenethylamine class. It has a similar mechanism of action as an amphetamine; however, its penetration into the central nervous system is more significant, and its duration of effect is longer. Hence, MA has the potential to be abused more often, which leads to dependency. Changes in the brain's reward system caused by addiction can lead abusers to suffer mental symptoms like anxiety, sadness, and psychosis [4].

Along with the increase numbers of MA abusers, the emergence of its psychiatric symptoms, and the lack of data on the profiles of MA abusers, we aimed to investigate the pattern and the profiles of MA abusers and its association with psychiatric symptoms. The results of the patterns and profiles of the MA abusers can guide regulators

and health professionals in Indonesia in designing the most appropriate program for the prevention and treatment of MA abuse.

MATERIALS AND METHODS

Population and sample

This was cross-sectional data in MA abusers admitted to the national narcotics rehabilitation center in Lido Bogor from January 2016 to December 2018. The study was conducted by analyzing medical records obtained upon admission of the MA abusers. The inclusion criteria were all of MA abusers aged 18 y and above. Assessment of psychiatric symptoms was evaluated according to Addiction Severity Index (ASI). The ASI, a semi-structured interview used to evaluate substance use disorders (SUD) patients and assessed by physicians who have been trained to used ASI. The ASI was developed to provide an assessment of patient functioning across seven problem areas, commonly SUD, including medical status, employment, history of drug use, alcohol use, illegal activity, family/social relationships, and psychiatric status. The Ethical Committee of the Faculty of Medicine Universitas Indonesia approved this study with the No of KET-621/UN2. F1/ETIK/PPM.00.02/2019.

Data analysis

Microsoft Excel and SPSS version 22.0 were used to process the data. The description of MA abusers profiles and characteristics were provided in the descriptive data. The association with psychiatric symptoms were analyzed using bivariate and multivariate analysis. The difference in proportion was analyzed using the Chi-square of Fisher's exact test. The bivariate analysis findings that fulfilled the multivariate standards ($p < 0.25$) were then used in the multivariate

analysis (logistic regression). The p value cutoff of 0.05 is considered statistically significant for any significant differences.

RESULTS

Out of the total of 1900 MA abusers' medical records, 1842 abusers meets the inclusion criteria, while 58 abusers were eliminated due to incomplete data. MA abusers' demographic profile includes age, gender, employment, last education, and marital status (table 1). Most of MA abusers were males between the age of 18-40 y old. Most abusers used MA in conjunction with other addictive substances, including cannabis, opioids, tranquilizers, hallucinogens, alcohol, and other amphetamine-type stimulants. The majority of the abusers used MA at a dose of more than 0.2 g per usage for a duration of less than 5 y. MA was administered via smoking or inhaled (table 1).

Out of the 1842 MA abusers, 770 (41.8%) patients were found to have psychiatric symptoms upon admission. The types of psychiatric symptoms assessed were anxiety, depression, and psychosis. The proportion of abusers with psychiatric symptoms is reported in table 2.

We then analyzed the association between demographic characteristics and profiles of MA abusers with psychiatric

symptoms using bivariate analysis, followed by multivariate analysis. The profile and method of abuse that showed a statistically significant association with psychiatric symptoms were female gender (OR 1.95; 95% CI: 1.25-3.04), more than 5-years duration of use (OR 1.41; 95% CI: 1.16-1.71), smoking as the route of administration (OR 1.3; 95% CI: 1.07-1.57), and use with other narcotics (OR 1.48; 95% CI 1.17-1.87) (table 3).

Upon the bivariate and multivariate analysis of individual psychiatric symptoms (anxiety, depression, and psychosis), we found different factors of characteristics that were associated with each symptoms. Results from the multivariate analysis shows that the female gender (OR 1.6; 95% CI: 1.0-2.55), MA dose of more than 0.2 g (OR 1.26; 95% CI: 1.0-2.55), smoking as the route of administration (OR 1.37; 95% CI: 1.06-1.71), and concomitant use with other narcotics (OR 1.47; 95% CI: 1.13-1.91) were among the factors that increased anxiety symptoms (table 3). The factors found to be significantly associated with depression and psychosis were female gender, 5-year duration of use and smoking. Concomitant use of other narcotics increased the risk of depression (OR 1.3; 95% CI 1.01-1.65), however, it has a neutral effect on psychosis (OR 1.29; 95% CI: 0.92-1.82) (table 3).

Table 1: Demographic characteristics and profiles of MA abusers that were admitted to the national rehabilitation center, Lido Bogor

Characteristics	Number (N=1842)	n (%)
Age (years)		
18-40	1702	92.4
Over 40	140	7.6
Gender		
Male	1753	95.2
Female	89	4.8
Employment		
Employed	1182	64.2
Unemployed	660	35.8
Marital status		
Single	1077	58.5
Married	765	41.5
Concomitant addictive substances used		
Cannabis	734	39.8
Opioids	34	1.8
Tranquilizer	66	3.6
Hallucinogens	5	0.3
Alcohols	831	45.1
Other ATS*	273	14.8
Patterns of MA abuse:		
<0.2	842	45.7
Dose (gram/each usage)		
≥ 0.2	1000	54.3
Duration (year)		
<5	1052	57.1
Route of administrations		
≥ 5	790	42.9
Smoked	937	50.9
Inhaled	905	49.1

*ATS = Amphetamine-type stimulant

Table 2: Proportions of MA abusers with psychiatric symptoms based on the addiction severity index (ASI)

Psychiatric symptoms	N	%
At least one psychiatric symptoms	770	41.8
Anxiety	452	24.5
Depression	588	31.9
Psychosis	164	8.9
Psychosis and depression	96	5.2
Psychosis and anxiety	83	4.5
Anxiety and depression	319	17.3
Anxiety, depression and psychosis	65	3.5

Table 3: Multivariate analysis of the factors associated with psychiatric symptoms in MA abusers based on the Addiction Severity Index

Characteristics	Adjusted odds ratio (95% CI)	p-value
Association with Psychiatric symptoms		
Gender Female vs Male	1.95 (1.25–3.04)	0.003
Dose ≥ 0.2 grams vs <0.2 grams	1.15 (0.91–1.35)	0.27
Duration ≥ 5 y vs <5 y	1.41 (1.16–1.71)	<0.001
Route of administration smoked vs inhaled	1.3 (1.07–1.57)	0.006
Concomitant use with other narcotics Yes vs no	1.48 (1.17–1.87)	0.001
Use with other types of ATS Yes vs no	1.25 (-0.92–1.7)	0.14
Use with opioids Yes vs no	1.83 (0.83–4.0)	0.12
Use with tranquilizer Yes vs no	1.39 (0.83–2.42)	0.23

	Characteristics	Adjusted odds ratio (95% CI)	p-value
Association with anxiety	Gender female vs male	1.6 (1.0–2.55)	0.04
	Dose ≥ 0.2 grams vs <0.2 grams	1.26 (1.01–1.57)	0.006
	Duration ≥ 5 y vs <5 y	1.22 (0.98–1.52)	0.07
	Route of administration smoked vs inhaled	1.37 (1.06–1.71)	0.04
	Concomitant use with other narcotics Yes vs no	1.47 (1.13–1.91)	0.004
	Use with other types of ATS Yes vs no	1.2 (0.86–1.67)	0.28
	Use with opioids Yes vs no	1.66 (0.78–3.52)	0.18
	Use with tranquilizer Yes vs no	1.45 (0.82–2.56)	0.19
	History of prior rehabilitation Yes vs no	1.43 (0.93–2.19)	0.09
Association with depression	Gender Female vs Male	1.75 (1.12–2.72)	0.01
	Duration ≥ 5 y vs <5 y	1.35 (1.11–1.66)	0.003
	Route of administration smoked vs inhaled	1.34 (1.09–1.64)	0.004
	Concomitant use with other narcotics Yes vs no	1.3 (1.01–1.65)	0.03
	Use with other types of ATS Yes vs no	1.42 (1.04–1.95)	0.02
	Use with opioids Yes vs no	0.88 (0.41–1.88)	0.75
	Use with tranquilizer Yes vs no	1.88 (1.08–3.26)	0.02
	Alcohol use Yes vs no	1.07 (0.87–1.31)	0.4
	History of prior rehabilitation Yes vs no	1.43 (0.93–2.19)	0.09
Association with psychosis	Gender Female vs Male	1.83 (0.98–3.4)	0.05
	Duration ≥ 5 y vs <5 y	1.46 (1.05–2.02)	0.02
	Route of administration smoked vs inhaled	0.66 (0.47–0.91)	0.01
	Concomitant use with other narcotics Yes vs no	1.29 (0.92–1.82)	0.13
	Cannabis use Yes vs no	2.71 (1.07–6.83)	0.03
	Opioids use Yes vs no	2.71 (1.07–6.83)	0.03
	Tranquilizer use Yes vs no	1.2 (0.54–2.7)	0.64

ATS = *ATS = Amphetamine-type stimulant

DISCUSSION

In the present study, we aimed to analyze the demographic profiles and characteristics of MA use associated with psychiatric symptoms, including anxiety, depression, and psychosis. We found several factors associated with the increased risk of psychiatric symptoms, such as gender, duration of use, route of administration and concomitant use with other narcotics.

Our study was done using a total sampling of patients admitted to the national rehabilitation center, Lido, Bogor, Indonesia from 2016 to 2018. This study's age range of MA abusers was dominated by the age group of 18–40 y. Our findings were in line with the studies from other regions in Asia that stated the average MA users were in their twenties to thirties [5, 6]. The majority of MA abusers also used other narcotics alongside MA. As reported by other studies, most abusers did so to replicate the effects they had when they initially started using opioids, primarily by combining MA with marijuana or alcohol [7–9]. In this study, similar proportions of MA abusers uses the high or low dose of MA (with the cut-off point of 0.2 g per usage). The need for different dose in each subject could be affected by the difference in metabolism and the longer duration of MA use [4, 10].

In the present study, we found a comparable proportion of smoking and inhalation as a method of MA administration. Other studies have shown that smoking is preferred because of the powerful euphoric impact that may be achieved as rapidly as intravenous treatment (approximately 2 min), while nasal delivery can takes about 5 min. Smoking also resulted in a higher bioavailability vs inhaled (90% vs 79%, respectively). The duration of MA use in our study was also like those found in other studies in Southeast Asian countries [12].

We found a high proportion of MA abusers with psychiatric symptoms (41.8%). The psychiatric symptoms assessed in this study were anxiety, depression, and psychosis. Psychiatric symptoms in MA abusers in this study were assessed from psychiatric addiction severity index domain. Psychiatric symptoms in MA users arise from prolonged duration of MA exposure, which has been demonstrated to cause neurotoxic and neuropathological effects. The most prevalent psychiatric symptom seen by MA users is depression [13, 14]. The proportion of psychiatric symptoms arising from MA use can differ in other populations. Different patterns of MA use and concomitant narcotic use may contribute to the differences between populations [13–15].

The multivariate analysis found that the demographic profile and method of MA abuse that had a statistically significant relationship

with psychiatric symptoms were gender, duration, route of administration and use with other narcotics. Psychiatric symptoms in MA abusers are more experienced by women than men. The increased risk in women might be attributed to the hormonal differences that resulted in different metabolism in women [4, 5]. It was reported that more psychiatric symptoms were found in MA abusers with a long duration of abuse. In this study, a duration of use of 5 y was more at risk of experiencing psychiatric symptoms than the duration of use <5 y. Our study agrees with other findings that the duration of MA use might predict the emergence of psychiatric symptoms [5, 16]. Smoking as the route of administration was more likely to increase psychiatric symptoms than the inhaled route. This is related to the difference in MA purity on the two routes. The form of MA in smoking is crystalline (ice meth), which has a purity of 60–80%. Even MA ice blue has a purity of almost 100%, while nasal powder (powder) with MA has a purity of 10% [17]. MA abusers often use MA with other narcotics (combinations) such as marijuana, opiates, different types of ATS, tranquilizers and hallucinogens. This combination is known to increase the risk of developing psychiatric symptoms because it will increase the toxicity of MA [18].

The results of multivariate analysis of the relationship between the demographic profile and the anxiety symptoms showed that the statistically significant variables were gender, dose, route of administration and use with other narcotics. In the previous study done by Glasner-Edward *et al.*, which examined the relationship between anxiety disorders, MA abuse and functional outcomes at a three-year follow-up, abusers who experienced anxiety had a significantly higher risk of being hospitalized for 12 mo [19]. The comorbidity of MA abuse and anxiety has implications for the course of the disease and treatment outcomes, so a comprehensive approach is needed to treat anxiety and co-occurring MA abuse. Symptoms of anxiety in women occurs twice as many (2:1) compared to men in MA abusers. These results were in line with the explanation above that there are differences in hormones and responding to stress between women and men. Different to the findings in the overall psychiatric symptoms, a higher dose of MA contributes to a higher risk of anxiety in MA abusers. The risk of Anxiety was also increased when smoking was used as a method of administration. As mentioned above, there were differences in the purity of MA crystalline forms. MA purity was linked to a higher risk of acquiring mental symptoms such as anxiety, sadness, and psychosis. MA abusers who used MA in conjunction with other opioids reported greater anxiety. The findings of this research are similar to those of a study by Hang Su *et al.*, which found that MA abusers who mix MA with other opioids are more likely to suffer

anxiety. These findings are corroborated by Jasmina Burdzovic *et al.*'s 10-year prospective analysis, which discovered that medication combinations were related to an increased prevalence of mental illnesses such as anxiety and depression [20, 21].

Gender, duration of use and the route of administration were the three main risks that increased the occurrence of depression and psychosis symptoms. According to the American Psychiatric Association, women are 1.5 to 2 times more likely than males to suffer from depression [5].

MA users often combine the use with other drugs such as tranquilizers and ATS. Anxiety, fear, tension, agitation, and memory disorder are all associated with tranquilizers usage. Another study discovered that the use of benzodiazepines might increase depression among MA users, with an OR of 2.1 [12]. The reason why abusers may take tranquilizers with MA is to lessen the effects of stimulants and dependency on MA. In contrast, the purpose of mixing with other ATS like ecstasy or methylenedioxymethamphetamine (MDMA) is to intensify the impact of MA. Stimulants are a kind of medicine that stimulates the central nervous system. Combining these medicines increases the chance of mental symptoms and increases the risk of cardiac issues and serotonin syndrome [16, 20].

According to previous research, MA may produce either long-term or short-term psychosis, often characterized by persecutory delusions, auditory and visual hallucinations, paranoia, and disordered speech. Unlike anxiety and depression, the inhaled administration route is more likely to trigger psychosis than smoking. This might be because the nasal route of administration can reach the brain directly through the olfactory and/or trigeminal nerve pathways [5]. MA increases the quantity of dopamine in the striatum, resulting in a large glutamate release in the cortex. This release will sometimes induce cortical interneuron injury, subsequently interfering with thalamocortical impulses, resulting in psychotic symptoms [5, 22, 23].

There are several limitations to this study. First, the data used is from secondary data, so it depends on the records in the Lido BNN medical records. The assessments of the way of abuse are based only on interviews, for example, on the duration, the first and last start of abusing the MA, which may result in recall bias. Another limitation of our study was that an accurate causality analysis could not be carried out between MA abusers and the onset of psychiatric symptoms. The nature of this study which was retrospective, might not eliminate other factors that influence the onset of psychiatric symptoms in MA abusers. The last limitation is the assessment of the psychiatric symptoms was based on ASI, not on DSM V.

The advantages of this study are the large number of samples and data taken from national rehabilitation center, Lido which is a national referral center from regions throughout Indonesia. Therefore, the findings in this study may be generalized to MA abusers in Indonesia. In addition, this study is the first to examine the profile and characteristics of MA abusers and its relationship to psychiatric symptoms.

CONCLUSION

Most psychiatric symptoms found in MA abusers were depression and anxiety. Female gender, longer duration of use, smoking as the route of administration and concomitant use with other narcotics are the factors that increase the risk of psychiatric symptoms among MA abusers. Our findings indicate that an early assessment of psychiatric symptoms and comprehensive management of MA abusers should be carried out. In addition, further prospective research is needed from the results obtained in this study.

FUNDING

Hibah PUTI 2022 from Universitas Indonesia.

AUTHORS CONTRIBUTIONS

All the authors have contributed equally.

CONFLICT OF INTERESTS

Declared none

REFERENCES

1. UNODC. UNO on D and C. Stimulants. 2019. Word Drug Report; 2019.
2. Badan narkotika nasional republik indonesia. Infografis survei prevalensi penyalahgunaan narkoba tahun; 2020.
3. BNN RI. Jurnal data puslitdatin tahun. J Data Puslitdatin. 2018;240.
4. Cruickshank CC, Dyer KR. A review of the clinical pharmacology of methamphetamine. *Addiction*. 2009;104(7):1085-99. doi: 10.1111/j.1360-0443.2009.02564.x, PMID 19426289.
5. Ma J, Sun XJ, Wang RJ, Wang TY, Su MF, Liu MX. Profile of psychiatric symptoms in methamphetamine users in China: greater risk of psychiatric symptoms with a longer duration of use. *Psychiatry Res*. 2018;262:184-92. doi: 10.1016/j.psychres.2018.02.017, PMID 29453037.
6. Sulaiman AH, Said MA, Habil MH, Rashid R, Siddiq A, Guan NC. The risk and associated factors of methamphetamine psychosis in methamphetamine-dependent patients in Malaysia. *Compr Psychiatry*. 2014;55Suppl 1:S89-94. doi: 10.1016/j.comppsy.2013.01.003, PMID 23433219.
7. Wang L, Min JE, Krebs E, Evans E, Huang D, Liu L. Polydrug use and its association with drug treatment outcomes among primary heroin, methamphetamine, and cocaine users. *Int J Drug Policy*. 2017;49:32-40. doi: 10.1016/j.drugpo.2017.07.009, PMID 28888099.
8. Hart CL, Gunderson EW, Perez A, Kirkpatrick MG, Comer SD, Foltin RW. Methamphetamine in Humans. 2016;33(8):1847-55.
9. Bujarski S, Roche D, Lunny K, Moallem NR, Courtney KE, Allen V. A community sample of methamphetamine users. 2015;127-32.
10. Su MF, Liu MX, Li JQ, Lappin JM, Li SX, Wu P. Epidemiological characteristics and risk factors of methamphetamine-associated psychotic symptoms. *Front Psychiatry*. 2018;9:489. doi: 10.3389/fpsy.2018.00489, PMID 30369888.
11. Rungrunrorn T, Verachai V, Gelernter J, Malison RT, Kalayasiri R. Sex differences in methamphetamine use and dependence in a Thai treatment center. *J Addict Med*. 2017;11(1):19-27. doi: 10.1097/ADM.0000000000000262, PMID 27649265.
12. Dimiceli LE, Sherman SG, Aramrattana A, Siriraj B, Celentano DD. Methamphetamine use is associated with high levels of depressive symptoms in adolescents and young adults in rural Chiang Mai province, Thailand. *BMC Public Health*. 2016;16(1):1-9. doi: 10.1186/s12889-016-2851-1.
13. Salo R, Flower K, Kielstein A, Leamon MH, Nordahl TE, Galloway GP. Psychiatric comorbidity in methamphetamine dependence. *Psychiatry Res*. 2011;186(2-3):356-61. doi: 10.1016/j.psychres.2010.09.014, PMID 21055832.
14. Bao YP, Qiu Y, Yan SY, Jia ZJ, Li SX, Lian Z. Pattern of drug use and depressive symptoms among amphetamine-type stimulants users in Beijing and G. Province, China. *PLOS One*. 2013;8(4):e60544. doi: 10.1371/journal.pone.0060544, PMID 23585838.
15. Lamyai W, Pono K, Indrakamhaeng D, Saengsin A, Songhong N, Khuwuthyakorn P. Risks of psychosis in methamphetamine users: a cross-sectional study in Thailand. *BMJ*. 2019;9(10):e032711. doi: 10.1136/bmjopen-2019-032711, PMID 31615802.
16. Zweben JE, Cohen JB, Christian D, Galloway GP, Salinardi M, Parent D. Psychiatric symptoms in methamphetamine users. *Am J Addict*. 2004;13(2):181-90. doi: 10.1080/10550490490436055, PMID 15204668.
17. Rigoni R, Woods S, Breeksema JJ. From opiates to methamphetamine: building new harm reduction responses in Jakarta, Indonesia. *Harm Reduct J*. 2019;16(1):67. doi: 10.1186/s12954-019-0341-3, PMID 31829253.
18. Jones CM, Compton WM, Mustaquim D. Patterns and characteristics of methamphetamine use among adults-United States, 2015-2018. *MMWR Morb Mortal Wkly Rep*. 2020;69(12):317-23. doi: 10.15585/mmwr.mm6912a1, PMID 32214077.
19. Hellem TL. A review of methamphetamine dependence and withdrawal treatment: A focus on anxiety outcomes. *J Subst Abuse Treat*. 2016;71:16-22. doi: 10.1016/j.jsat.2016.08.011, PMID 27776672.
20. Su H, Zhang J, Ren W, Xie Y, Tao J, Zhang X. Anxiety level and correlates in methamphetamine-dependent patients during

- acute withdrawal. *Medicine (Baltimore)*. 2017;96(15):e6434. doi: 10.1097/MD.00000000000006434, PMID 28403074.
21. Burdzovic Andreas J, Lauritzen G, Nordfjaern T. Co-occurrence between mental distress and poly-drug use: A ten year prospective study of patients from substance abuse treatment. *Addict Behav*. 2015;48:71-8. doi: 10.1016/j.addbeh.2015.05.001, PMID 26004857.
22. Ware OD, Manuel JI, Huhn AS. Adults with opioid and methamphetamine co-use have lower odds of completing short-term residential treatment than other opioid co-use groups: a retrospective health services study. *Front Psychiatry*. 2021;12:784229. doi: 10.3389/fpsy.2021.784229. PMID 34955930.
23. Palmer A, Scott N, Dietze P, Higgs P. Motivations for crystal methamphetamine-opioid co-injection/co-use amongst community-recruited people who inject drugs: A qualitative study. *Harm Reduct J*. 2020;17(1):14. doi: 10.1186/s12954-020-00360-9, PMID 32106854.



ISSN 0975-7058

International Journal of Applied Pharmaceutics



Enhance Your Research Horizon by Our Blog

 07-05-2022

Enhance Your Research Horizon by Our Blog

Visit <https://innovareacademics.in/blog/> and learn how to write any post and publish it as a author (Totally Free of Cost).

For more and complete information, please click below on Read More

READ MORE 

Alert

 2022-03-29

International Journal of Applied Pharmaceutics (Int J App Pharm) is a peer-reviewed, bimonthly (onward March 2017) open access journal devoted to the excellence and research in the pure pharmaceutics. This Journal publishes original research work that contributes significantly to further the scientific knowledge in conventional dosage forms, formulation development and characterization, controlled and novel drug delivery, biopharmaceutics, pharmacokinetics, molecular drug design, polymer-based drug delivery, nanotechnology, nanocarrier based drug delivery, novel routes and modes of delivery; responsive delivery systems, prodrug design, development and characterization of the targeted drug delivery systems, ligand carrier interactions etc. However, the other areas which are related to the pharmaceutics are also entertained includes physical pharmacy and API (active pharmaceutical ingredients) analysis. The Journal publishes original research work either as a Original Article or as a Short Communication. Review Articles on a current topic in the said fields are also considered for publication in the Journal.

Abstracting and Indexing

Google Scholar, Scopus, EMBASE, SCI mago (SJR), CNKI (China Knowledgege Resource Integrated Database), CAS, CASSI (American Chemical Society), Open-J-Gate, OAI, LOCKKS, OCLC (World Digital Collection Gateway), UIUC.

UGC Listed Journal

Most Viewed Articles

[DEVELOPMENT AND EVALUATION OF TIOCONAZOLE LOADED EMULGEL](#)



[HOME](#) / [About the Journal](#)

About the Journal

Focus and Scope

International Journal of Applied Pharmaceutics (Int J App Pharm) is a peer-reviewed, bimonthly (onward March 2017) open access journal devoted to the excellence and research in the pure pharmaceutics. This Journal publishes original research work that contributes significantly to further the scientific knowledge in conventional dosage forms, formulation development and characterization, controlled and novel drug delivery, biopharmaceutics, pharmacokinetics, molecular drug design, polymer-based drug delivery, nanotechnology, nanocarrier based drug delivery, novel routes and modes of delivery; responsive delivery systems, prodrug design, development and characterization of the targeted drug delivery systems, ligand carrier interactions etc. However, the other areas which are related to the pharmaceutics are also entertained includes physical pharmacy and API (active pharmaceutical ingredients) analysis. The Journal publishes original research work either as a Original Article or as a Short Communication. Review Articles on a current topic in the said fields are also considered for publication in the Journal.

Publication Frequency


The journal had started in 2009 with quaterly publication frequency. It is bimonthly onwards March 2017.

Open Access Policy

This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge. [For More Details Click Here](#)

Peer Review Process

The IJAP follows Double Blind Peer Review System. The detailed peer review flow is shown below:



Peer Review & Publication Policy

For details please [Click Here](#)

Publication Ethics

For details please [Click Here](#)



[HOME](#) / Editorial Board

Editorial Board

Editor-in-Chief

[Dr. Gaurav Kant Saraogi](#)

Sri Aurobindo Institute of Pharmacy, Indore-Ujjain State Highway, Indore, Madhya Pradesh, India

Email: editor@ijaponline.org, gauravsaraogi13@gmail.com

Associate Editors

[Dr. Genta Ida](#)

Department of Drug Sciences, University of Pavia, Italy

Email: ida.genta@unipv.it

Assistant Editors

[Dr. Awesh Kumar Yadav](#)

National Institute of Pharmaceutical Education and Research Raebareli, Uttar Pradesh, India

Email: aweshyadav@gmail.com

[Dr. Arvind Gulbake](#)

National Institute of Pharmaceutical Education and Research: Changsari, Assam, India

Email: arvind.gulbake@gmail.com

Editorial Members

[Dr. Kailash C. Petkar](#)

Scientist 'C', Government of India, DSIR, Min. of Science and Technology, New Delhi, India

Email: petkar.kailash@gmail.com

[Dr. Tarang Nema](#)

International Flavours and Fragrances, Singapore

[Dr. Carlotta Marianecchi](#)

Dipartimento di Chimica e Tecnologie del Farmaco, Sapienza Universita di Roma, Rome, Italy

[Dr. Manoj Nahar](#)

Sun Pharmaceutical Industries Limited, Vadodara, Gujarat, India

Email: mnjnahar@yahoo.co.in

[Dr. Tarek Abdelnaby Ahmed](#)

Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, KAU, Jeddah, KSA

Email: dr_tarek_nour@yahoo.com

[Dr. Elizabeth Igne Ferreira](#)

Faculty of Pharmaceutical Sciences, University of Sao Paulo, Brazil

Email: elizabeth.igne@gmail.com

[Dr. Surya Prakasarao Kovvasu](#)

Western University of Health Sciences, Pomona, California, USA

Email: skovvasu@westernu.edu

[Dr. N. Kanagathara](#)

Saveetha School of Engineering, Saveetha University, Chennai, India

Email: kanagathara23275@gmail.com

[Dr. Mohammed Elmowafy Gomaa Aburaia](#)

Department of Pharmaceutics, College of Pharmacy, Jouf University, Saudi Arabia

Email: melmowafy@ju.edu.sa

[Dr. Liang Chen](#)

Wenzhou Medical University, Wenzhou, P. R. China

Email: cheng_zhuan0101@wuxibiologics.com

[Dr. Franca Castiglione](#)

Department "G. Natta", Politecnico di Milano, Italy

Email: franca.castiglione@polimi.it

[Dr. Iman Emam Omar Gomaa](#)

Faculty of Pharmacy, University for Modern Sciences and Arts (MSA)" Cairo - Egypt

Email: igomaa@msa.eun.eg

[Dr. Basant Amarji](#)

UIPS, Punjab University, Chandigarh, Punjab, India

Email: basantamarji@gmail.com

[Dr. Rabab Kamel](#)

Pharmaceutical Technology Department, National Research Centre, Egypt

Email: drrababk@hotmail.com

[Dr. Satish Shilpi](#)

Ravishankar College of Pharmacy, Bhopal, MP, India

Email: shilpisatish@gmail.com

[Dr. Umeyor Chukwuebuka Emmanuel](#)

Faculty of Pharmaceutical Sciences, Nnamdi Azikiwe University, Awka, Anambra State, Nigeria

Email: ec.umeyor@unizik.edu.ng

[Dr. Yosra S.R. Elnaggar](#)

Faculty of Pharmacy and Drug Manufacturing, Pharos University, Alexandria, Egypt

Email: yosra_pharm@yahoo.com

[Dr. Sumeet Kapoor](#)

IIT New Delhi, India

Email: s.kapooriitd@gmail.com



Online ISSN: 0975–7058

INDEXED By
Scopus

CONTINUED IN 2023

How we claim? [Click Scopus indexing IJAP 2023](#) to learn and understand

1.5

2021
CiteScore

42nd percentile

Powered by **Scopus**



Plagiarism Check



Embase

It's Embase, Not Expanded Embase, [Learn in 1 Min](#)

MOST READ

[OVERVIEW ON FLOATING DRUG DELIVERY SYSTEM](#)

👁 926

[OCULAR DRUG DELIVERY SYSTEM: CHALLENGES AND APPROACHES](#)

👁 894

[PHARMACEUTICAL QUALITY AUDITS: A REVIEW](#)

👁 486

[FORMULATION AND EVALUATION OF TRANSDERMAL PATCHES OF PANTOPRAZOLE SODIUM](#)

👁 348

[DERMATOLOGIC GELS SPREADABILITY MEASURING METHODS COMPARATIVE STUDY](#)

👁 333

Our Journals || Open Access Policy || Publication & Peer Review Policy || Publication EthicsThe publication is licensed under a **Creative Commons License** (CC BY). [View Legal Code](#)Copyright © 2021 All Rights Reserved, **Innovare Academic Sciences** | Powered By **CyberDairy**



[HOME](#) / [ARCHIVES](#) / Vol 14, Special Issue 5 (Dec), 2022

Vol 14, Special Issue 5 (Dec), 2022

5th International Seminar on Pharmaceutical Science and Technology (ISPST)-3rd International Seminar and Expo on Jamu-13th Annual ISCC 2022.

Guest Editor: [Dr. Apt., Yasmiwar Susilawati M.Si](#)

PUBLISHED: 27-12-2022

REVIEW ARTICLE(S)

QUST AL HINDI (SAUSSUREA LAPPA): A NARRATIVE REVIEW OF ITS PHYTOCHEMISTRY AND PHARMACOLOGICAL POTENTIAL AGAINST COVID-19

SUKMAWATI S., IDA MUSFIROH, MUCHTARIDI, ADRYAN FRISTIOHADY

1-7

[VIEW ABSTRACT](#)

[PDF](#)

[DOWNLOAD PDF](#)

[10.22159/ijap.2022.v14s5.17](#)

NATURAL PLANT REMEDIES FOR DEPRESSION DURING THE COVID-19 PANDEMIC, UPDATE REVIEW

GOFARANA WILAR, SRI BETHA PUTRI, BUNGA MUSTIKAWATI KUSMARA, KIVA AGITA

8-14

[VIEW ABSTRACT](#)

[PDF](#)

[DOWNLOAD PDF](#)

[10.22159/ijap.2022.v14s5.18](#)

A REVIEW OF SUNKAI (PERONEMA CANESCENS): TRADITIONAL USAGE, PHYTOCONSTITUENT, AND PHARMACOLOGICAL ACTIVITIES

MUHAMMAD RYAN RADIX RAHARDHIAN, YASMIWAR SUSILAWATI, ADI SUMIWI, MOELYONO MUKTIWARDYO, MUCHTARIDI

15-23

[VIEW ABSTRACT](#)

[PDF](#)

[DOWNLOAD PDF](#)

[10.22159/ijap.2022.v14s5.24](#)

CHEMICAL AND PHARMACOLOGICAL PROPERTIES OF SELECTED MEDICINAL PLANT

SPECIES FROM GENUS PREMNA AND THEIR IMMUNOMODULATORY POTENTIALS

ANDHARA MARSHA BELINDA, RADEN M. FEBRIYANTI, MUHAIMIN

24-31

 VIEW ABSTRACT PDF DOWNLOAD PDF

10.22159/ijap.2022.v14s5.30

ORIGINAL ARTICLE(S)

SYNTHESIS OF MOLECULAR IMPRINTED POLYMER SALBUTAMOL USING METHACRYLIC ACID MONOMER AND TRIMETHYL PROPANE TRIMETHACRYLATE (TRIM) AS A CROSS-LINKER THROUGH SUSPENSION POLYMERIZATION

IKE SUSANTI, NISA SAFITRI, RIMADANI PRATIWI, ALIYA NUR HASANAH

32-39

 VIEW ABSTRACT PDF DOWNLOAD PDF

10.22159/ijap.2022.v14s5.01

B-LACTAMASES INHIBITOR-PRODUCING SOIL BACTERIA FOR AMPICILLIN-RESISTANT UROPATHOGENIC ESCHERICHIA COLI ISOLATE

SRI AGUNG FITRI KUSUMA, VALENTINA YURINA, DEBBIE S. RETNONINGRUM, INDAH LAILY HILMI, SUSI AFRIANTI RAHAYU, YUNI NOER ANGGRAINI

40-44

 VIEW ABSTRACT PDF DOWNLOAD PDF

10.22159/ijap.2022.v14s5.03

STABILITY OF OMEGA-3 COMPOUNDS COMPLEX WITH PPAR- α RECEPTOR AS AN ANTI-OBESITY USING MOLECULAR DYNAMIC SIMULATION

IDA MUSFIROH, GINNA MEGAWATI, DEWI M. D. HERAWATI, MUS IFAYA

45-49

 VIEW ABSTRACT PDF DOWNLOAD PDF

10.22159/ijap.2022.v14s5.04

POTENTIAL OF KABAU LEAF ETHANOL EXTRACT (ARCHIDENDRON BUBALINUM (JACK.) I. C. NIELSEN) TO DECREASE OF BLOOD GLUCOSE LEVELS INDUCED ALLOXAN

HESTI RIASARI, DIKI PRAYUGO WIBOWO, NOVI IRWAN FAUZI

50-55

 VIEW ABSTRACT PDF DOWNLOAD PDF

10.22159/ijap.2022.v14s5.05

ANTIBACTERIAL ACTIVITY AND BIOAUTOGRAPHIC EVALUATION OF EXTRACT AND FRACTION FROM TAMOENJU (HIBISCUS SURATTENSIS L.) LEAVES

YULIET, AKHMAD KHUMAI, NUR HIKMA, NURINAYAH

56-59

 [VIEW ABSTRACT](#) [PDF](#) [DOWNLOAD PDF](#)[10.22159/ijap.2022.v14s5.07](#)

EFFECT OF HEAT TREATMENT ON POTASSIUM CONTENT AND ANTI-SHIGELLOSIS
ACTIVITY OF KLUTUK BANANAS (MUSA BALBISIANA COLLA) FRUIT FLOUR

SRI AGUNG FITRI KUSUMA, DANNI RAMDHANI, EMMANUEL MELATI SETIAFIANTI

60-66

 [VIEW ABSTRACT](#) [PDF](#) [DOWNLOAD PDF](#)[10.22159/ijap.2022.v14s5.10](#)

ANTIBACTERIAL ACTIVITY OF LIQUID CRYSTAL NANOPARTICLES GEL OF BINJAI LEAVES
METHANOL EXTRACT (MANGIFERA CAESIA JACK. EX. WALL.) AGAINST
PROPIONIBACTERIUM ACNES

HAFIZ RAMADHAN, DYERA FORESTRYANA, WAHYUDIN BIN JAMALUDIN, SATRIYO KRISNA PALGUNO

67-71

 [VIEW ABSTRACT](#) [PDF](#) [DOWNLOAD PDF](#)[10.22159/ijap.2022.v14s5.11](#)

STANDARDIZATION OF ORTHOSIPHON ARISTATUS, BLUME MIQ

FAHRAUK FARAMAYUDA, SORAYA RIYANTI, SURYANI, AKHIRUL KAHFI SYAM, ELFAHM, TOTIK MARIANI,
SUKRASNO

72-79

 [VIEW ABSTRACT](#) [PDF](#) [DOWNLOAD PDF](#)[10.22159/ijap.2022.v14s5.12](#)

SCREENING OF ASHITABA (ANGELICA KEISKEI K.) COMPOUNDS AS POTENTIAL
MYCOBACTERIUM TUBERCULOSIS KASA INHIBITORS

AIYI ASNAWI, ELLIN FEBRINA, WIDHYA ALIGITA, DEWI KURNIA, LA ODE AMAN, ANNE YULIANTINI

80-85

 [VIEW ABSTRACT](#) [PDF](#) [DOWNLOAD PDF](#)[10.22159/ijap.2022.v14s5.13](#)

PREDICTION OF THE EFFECT OF SINGLE NUCLEOTIDE POLYMORPHISMS (SNPS) IN THE
CYP2C9 ON WARFARIN METABOLISM BY IN SILICO STUDY

NORISCA ALIZA PUTRIANA, TAOFIK RUSDIANA, TINA ROSTINAWATI, MOHAMMAD RIZKI AKBAR, SANDRA
MEGANTARA, SABRANAH HIDAYANTI

86-88

 [VIEW ABSTRACT](#) [PDF](#) [DOWNLOAD PDF](#)[10.22159/ijap.2022.v14s5.14](#)

IN SILICO STUDY OF CHEMICAL COMPOUNDS FROM ARECA NUT (ARECA CATECHU L.) ON

GABAA RECEPTOR AS ANTI-INSOMNIA CANDIDATES

RESMI MUSTARICHIE, SANDRA MEGANTARA, NYI MEKAR SAPTARINI, SARAH HUSNA HAYATI

89-95

 VIEW ABSTRACT PDF DOWNLOAD PDF[10.22159/ijap.2022.v14s5.15](#)

PATTERNS OF METHAMPHETAMINE USE AND ITS ASSOCIATIONS WITH PSYCHIATRIC SYMPTOMS IN PATIENTS UPON ADMISSION AT THE NATIONAL REHABILITATION CENTER LIDO BOGOR, INDONESIA

ROHMANIKA, WAWAIMULI AROZAL, MELVA LOUISA, ANGGI GAYATRI, ARIA KEKALIH, JEFMAN EFENDI MARZUKI HY, ERNIAWATI LESTARI, DIAH SETIA UTAMI

96-100

 VIEW ABSTRACT PDF DOWNLOAD PDF[10.22159/ijap.2022.v14s5.16](#)

PROFILE OF ANTIBIOTIC RESISTANCE AGAINST INFLUENZA IN ADULT PATIENTS: A CASE STUDY AT CITY HEALTH CENTER IN INDONESIA

DANNI RAMDHANI, SRI AGUNG FITRI KUSUMA, SHINTA NUR AZIZAH, IKA KHUMAIROH, HILARIUS BAP, DEDE SEDIANA

101-104

 VIEW ABSTRACT PDF DOWNLOAD PDF[10.22159/ijap.2022.v14s5.20](#)

A SERIES OF SIMPLE DECONTAMINATION METHODS OF BACTERIAL FLORA FOUND ON MUSICAL WIND INSTRUMENTS

SRI AGUNG FITRI KUSUMA, WAHYU PURWITA SARI, DEWI RUSMIATI

105-109

 VIEW ABSTRACT PDF DOWNLOAD PDF[10.22159/ijap.2022.v14s5.21](#)

ANTIDIABETIC ACTIVITY OF NOVEL CHROMENE COMPOUND ISOLATED FROM PEPEROMIA PELLUCIDA L. KUNTH AND IN SILICO STUDY AGAINST DPP-IV, ALPHA-GLUCOSIDASE, ALPHA-AMYLASE, AND ALDOSE REDUCTASE FOR BLOOD GLUCOSE HOMEOSTASIS

YASMIWAR SUSILAWATI, SANDRA MEGANTARA, JUTTI LEVITA

110-116

 VIEW ABSTRACT PDF DOWNLOAD PDF[10.22159/ijap.2022.v14s5.22](#)

ALPHA-GLUCOSIDASE INHIBITOR ACTIVITIES AND PHYTOCHEMICALS SCREENING OF THE PEPEROMIA GENUS CULTIVATED IN INDONESIA

SYUMILLAH SAEPUDIN, YASMIWAR SUSILAWATI

117-122

[VIEW ABSTRACT](#)[PDF](#)[DOWNLOAD PDF](#)

10.22159/ijap.2022.v14s5.23

COST-EFFECTIVENESS ANALYSIS OF ANTIBIOTIC USAGE IN DIABETIC FOOT ULCUS
PATIENTS IN DOKTER SOEKARDJO TASIKMALAYA HOSPITAL

NUR RAHAYUNINGSIH, ALLFI LAILLA PRATIWI, ANISA PEBIANSYAH

123-126

[VIEW ABSTRACT](#)[PDF](#)[DOWNLOAD PDF](#)

10.22159/ijap.2022.v14s5.25

NEUROPROTECTIVE AND ANTIOXIDANT ACTIVITIES OF AQUEOUS EXTRACT MORINGA
OLEIFERA LEAVES

EMNI PURWONINGSIH, WAWAIMULI AROZAL, HEE J. LEE, ABDUL MUNIM

127-131

[VIEW ABSTRACT](#)[PDF](#)[DOWNLOAD PDF](#)

10.22159/ijap.2022.v14s5.26

VALIDATION OF WARFARIN ANALYSIS METHOD IN HUMAN BLOOD PLASMA USING HIGH-
PERFORMANCE LIQUID CHROMATOGRAPHY WITH FLUORESCENCE DETECTION

NORISCA ALIZA PUTRIANA, TAOFIK RUSDIANA, TINA ROSTINAWATI, MOHAMMAD RIZKI AKBAR, ILMA
NURFUADAH

132-138

[VIEW ABSTRACT](#)[PDF](#)[DOWNLOAD PDF](#)

10.22159/ijap.2022.v14s5.27

OPTIMIZATION OF ACYCLOVIR SUSPENSION: FORMULATING DEVELOPMENT USING NA-
CMC AND QUALITY CONTROL OF FINISHED PRODUCTS

RESMI MUSTARICHIE, DRAJAD PRIAMBODO, DANNI RAMDHANI, NYI MEKAR SAPTARINI

139-142

[VIEW ABSTRACT](#)[PDF](#)[DOWNLOAD PDF](#)

10.22159/ijap.2022.v14s5.28

GC-MS PROFILE AND ANTIBACTERIAL ACTIVITY OF ESSENTIAL OIL FROM
STROBILANTHES KALIMANTANENSIS LEAVES: A NEW SPECIES FROM EAST KALIMANTAN,
INDONESIA

WISNU CAHYO PRABOWO, ANGGA CIPTA NARSA, DZAKI BAYU ANDARISTA, HADI KUNCORO, SRI AGUNG
FITRI KUSUMA, YASMIWAR SUSILAWATI

143-147

[VIEW ABSTRACT](#)[PDF](#)[DOWNLOAD PDF](#)

10.22159/ijap.2022.v14s5.29

ETHNOMEDICINAL STUDY OF UBAR KAMPUNG FOR DIABETES MELLITUS: INDIGENOUS KNOWLEDGE, BELIEF, AND PRACTICE OF MEDICINAL, AROMATIC, AND COSMETIC (MAC) PLANTS IN SUNDA REGION, WEST JAVA, INDONESIA

R. M. FEBRIYANTI, L. J. SLIKKERVEER, H. P. SPAINK, K. LESTARI, K. SAEFULLAH

148-153

 [VIEW ABSTRACT](#)

 [PDF](#)

 [DOWNLOAD PDF](#)

[10.22159/ijap.2022.v14s5.31](#)

THE POTENTIAL OF LANGIR (ALBIZIA SAPONARIA LOUR.) STEM BARK AS ANTI-DANDRUFF: IN SILICO AND IN VITRO STUDIES

HIMANIARWATI, MUHAMMAD ARBA, YASMIWAR SUSILAWATI, RESMI MUSTARICHIE

154-161

 [VIEW ABSTRACT](#)

 [PDF](#)

 [DOWNLOAD PDF](#)

[10.22159/ijap.2022.v14s5.33](#)

IDENTIFICATION OF FLAVONOIDS FROM ACALYPHA INDICA L. (EUPHORBIACEAE) AS CASPASE-3 ACTIVATORS USING MOLECULAR DOCKING AND MOLECULAR DYNAMICS

ELLIN FEBRINA, AIYI ASNAWI, RIZKY ABDULAH, KERI LESTARI, UNANG SUPRATMAN

162-166

 [VIEW ABSTRACT](#)

 [PDF](#)

 [DOWNLOAD PDF](#)

[10.22159/ijap.2022.v14s5.34](#)



Online ISSN: 0975-7058

INDEXED By
Scopus

CONTINUED IN 2023

How we claim? [Click Scopus indexing IJAP 2023](#) to learn and understand

1.5

2021
CiteScore

42nd percentile

Powered by **Scopus**

Plagiarism Check

**Embase**It's Embase, Not Expanded Embase, **Learn in 1 Min**

MOST READ

OVERVIEW ON FLOATING DRUG DELIVERY SYSTEM

👁 926

OCULAR DRUG DELIVERY SYSTEM: CHALLENGES AND APPROACHES

👁 894

PHARMACEUTICAL QUALITY AUDITS: A REVIEW

👁 486

FORMULATION AND EVALUATION OF TRANSDERMAL PATCHES OF PANTOPRAZOLE SODIUM

👁 348

DERMATOLOGIC GELS SPREADABILITY MEASURING METHODS COMPARATIVE STUDY

👁 333

Our Journals || Open Access Policy || Publication & Peer Review Policy || Publication EthicsThe publication is licensed under a **Creative Commons License** (CC BY). **View Legal Code**

